nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.02.2022 | editorial

New frontiers in chronic lymphocytic leukemia on the way to curing the disease

verfasst von: Univ.-Prof. Dr. Philipp Staber

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world and is considered to be incurable. In the last 10 years, novel therapeutics, like B cell receptor blockers and the bcl‑2 inhibitor venetoclax have transformed the prognosis for CLL patients [1]. In this issue of the Magazine of European Medical Oncology (MEMO), we discuss the perspectives of novel strategies to actually cure CLL patients. …

Vorheriger Artikel Innovative strategies in gastrointestinal cancer

Nächster Artikel Toxicity management in severe and refractory cases—what we have learned

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60.CrossRef

Heintel D. BTKi, venetoclax, obinutuzumab: what is the ideal combination?. memo. 2021. https://doi.org/10.1007/s12254-021-00776-4.CrossRef

Prochazka KT, Uhl B. Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?. memo. 2021. https://doi.org/10.1007/s12254-021-00778-2.CrossRefPubMedPubMedCentral

Bohn J-P. New actionable targets and investigational drugs in chronic lymphocytic leukemia. memo. 2021. https://doi.org/10.1007/s12254-021-00755-9.CrossRef

Titel: New frontiers in chronic lymphocytic leukemia on the way to curing the disease
verfasst von: Univ.-Prof. Dr. Philipp Staber
Publikationsdatum: 01.02.2022
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-022-00795-9

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Clinical challenges in the management of endocrine side effects of immuno-oncological therapies

Innovative strategies in metastatic gastric cancer: a short review

Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab

Thyroid metastasectomy for deposits from colorectal cancer: case report and non-systematic review

Immunotherapy—another breakthrough in gastrointestinal malignancies

Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations